SCHEMBL4491774

SCHEMBL4491774

CCCCCCCCCCOCC(C)(C)C

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.55
HTT P42858 2/20 0.48
THRB P10828 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
MAPT P10636 1/20 0.48
CES2 O00748 2/20 0.45
ALDH1A1 P00352 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
USP2 O75604 1/20 0.42
GBA2 Q9HCG7 2/20 0.40
TSHR P16473 2/20 0.40
SPHK1 Q9NYA1 1/20 0.37
LPAR1 Q92633 2/20 0.37
LPAR3 Q9UBY5 2/20 0.37
LPAR2 Q9HBW0 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25762054 1.00 CES1 (0.55) CES1HTTTHRBMEN1KMT2A
SCHEMBL25762056 1.00 CES1 (0.55) CES1HTTTHRBMEN1KMT2A
SCHEMBL4488321 1.00 CES1 (0.55) CES1HTTTHRBMEN1KMT2A
SCHEMBL25762058 1.00 CES1 (0.55) CES1HTTTHRBMEN1KMT2A
SCHEMBL4491457 1.00 CES1 (0.55) CES1HTTTHRBMEN1KMT2A
SCHEMBL4483157 1.00 CES1 (0.55) CES1HTTTHRBMEN1KMT2A
SCHEMBL534064 1.00 CES1 (0.55) CES1HTTTHRBMEN1KMT2A
SCHEMBL4489271 1.00 CES1 (0.55) CES1HTTTHRBMEN1KMT2A
SCHEMBL4506308 1.00 CES1 (0.55) CES1HTTTHRBMEN1KMT2A
SCHEMBL25762059 1.00 CES1 (0.55) CES1HTTTHRBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1655291-B1 COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM SHIONOGI & CO (JP) 2016-08-03 EP disclosed
US-20090318513-A1 COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM SHIONOGI & CO., LTD. 2009-12-24 US disclosed
US-7601746-B2 Compounds exhibiting thrombopoietin receptor agonism SHIONOGI & CO., LTD. (JP) 2009-10-13 US disclosed
US-20070043087-A1 Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid EDDINGPHARM (HONG KONG) COMPANY LIMITED (CN) 2007-02-22 US disclosed
EP-1655291-A1 COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM SHIONOGI & CO., LTD. (JP) 2006-05-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318513-A1 COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM MPL, TEK, GHRHR CES1 1766/4885HTT 1255/4885THRB 92/4885
US-20070043087-A1 Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid DHFR, NAT1, ACR CES1 322/4885HTT 1183/4885THRB 2080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.